title: A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
abstract: OBJECTIVE
  To test efficacy and tolerability of non-platinum regimens for advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Chemonaive patients with measurable stage IIIB/IV NSCLC treated with gemcitabine and cisplatin (GC), or gemcitabine and docetaxel (GD), maximumsix cycles in a phase IIB trial.
  
  
  RESULTS
  A total of 108 patients were randomized. Response rates (GC vs. GD, respectively): complete 3.6/2.0%, Partial 30.9/38.0%. Median Overall Survival (OS): 8.9 months in both groups (P = 0.53); and median time to progression (TTP): 6.2/5.5 months respectively (P = 0.61). Toxicities included (GC vs. GD, respectively): grade 3-4 neutropenia 49.1/41.2%; grade 3 thrombocytopenia 30.9/3.9%; grade 3 anemia 14.5/3.9%. Non-haematological toxicity was similar, except for nausea and vomiting, (16.3/2%); renal toxicity (3.7/0%) and hepatic toxicity (5.6/12.7%).
  
  
  CONCLUSIONS
  With a higher overall response rate and lower toxicity, GD is a good first treatment option for advanced NSCLC.
authors.affiliation: Department of Medical Oncology, Hospital do Meixoeiro, C/Meixoeiro, s/n, 36200, Vigo (Pontevedra), Spain. joaquin.casal.rubio@sergas.es
authors.forename: Joaquín Casal
authors.initials: JC
authors.lastname: Rubio
authors.forename: S
authors.initials: S
authors.lastname: Vázquez
authors.forename: F
authors.initials: F
authors.lastname: Vázquez
authors.forename: M
authors.initials: M
authors.lastname: Amenedo
authors.forename: J L
authors.initials: JL
authors.lastname: Fírvida
authors.forename: J R
authors.initials: JR
authors.lastname: Mel
authors.forename: G
authors.initials: G
authors.lastname: Huidobro
authors.forename: E
authors.initials: E
authors.lastname: Alvarez
authors.forename: M
authors.initials: M
authors.lastname: Lázaro
authors.forename: G
authors.initials: G
authors.lastname: Alonso
authors.forename: I
authors.initials: I
authors.lastname: Fernández
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018287:Carcinoma, Large Cell / Q000188:drug therapy* / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine